Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
MARKHAM, ON, Oct. 1, 2025 /CNW/ - Astellas Pharma Canada Inc. is proud to announce that VYLOY® (zolbetuximab) is now funded by the Ontario Drug Benefit Program under the New Drug Funding Program...
XTANDI is the first and only androgen receptor pathway inhibitor (ARPI) indicated and reimbursed in Ontario for use in patients with nmCSPC with biochemical recurrence at high risk for metastasis...
VEOZAH® (fezolinetant film-coated tablets) Now Available in Canada, First and Only Non-hormonal NK3 Antagonist Indicated for Vasomotor Symptoms (VMS) Associated with Menopause New treatment...
MARKHAM, ON, March 3, 2025 /CNW/ - Astellas Pharma Canada Inc. is pleased to share new findings from the Menopause Experience & Attitudes Study (MEAS), an international study examining societal...
Astellas Receives Health Canada Approval for VYLOY® (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer VYLOY is the first and only therapy...
Follow Canada news